ECSP16088687A - Composiciones novedosas, usos y métodos para hacerlas - Google Patents

Composiciones novedosas, usos y métodos para hacerlas

Info

Publication number
ECSP16088687A
ECSP16088687A ECIEPI201688687A ECPI201688687A ECSP16088687A EC SP16088687 A ECSP16088687 A EC SP16088687A EC IEPI201688687 A ECIEPI201688687 A EC IEPI201688687A EC PI201688687 A ECPI201688687 A EC PI201688687A EC SP16088687 A ECSP16088687 A EC SP16088687A
Authority
EC
Ecuador
Prior art keywords
methods
make
novel compositions
present
compounds
Prior art date
Application number
ECIEPI201688687A
Other languages
English (en)
Inventor
Mustapha Haddach
Original Assignee
Pimera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54393079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP16088687(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pimera Inc filed Critical Pimera Inc
Publication of ECSP16088687A publication Critical patent/ECSP16088687A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Generalmente, la presente invención proporciona compuestos de quinolona novedosos y composición farmacéutica de los mismos que pueden inhibir la proliferación celular y/o inducir la apoptosis celular. La presente invención también proporciona métodos para preparar tales compuestos y composiciones, y métodos para fabricar y usar el mismo.
ECIEPI201688687A 2014-05-09 2016-11-17 Composiciones novedosas, usos y métodos para hacerlas ECSP16088687A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461991282P 2014-05-09 2014-05-09
US201462050202P 2014-09-15 2014-09-15
US201462054054P 2014-09-23 2014-09-23
US201562128208P 2015-03-04 2015-03-04

Publications (1)

Publication Number Publication Date
ECSP16088687A true ECSP16088687A (es) 2017-01-31

Family

ID=54393079

Family Applications (3)

Application Number Title Priority Date Filing Date
ECIEPI201688687A ECSP16088687A (es) 2014-05-09 2016-11-17 Composiciones novedosas, usos y métodos para hacerlas
ECIEPI201731525A ECSP17031525A (es) 2014-05-09 2017-05-23 Composiciones novedosas, usos y métodos para hacerlas
ECSENADI201849420A ECSP18049420A (es) 2014-05-09 2018-06-29 Composiciones novedosas, usos y métodos para hacerlas

Family Applications After (2)

Application Number Title Priority Date Filing Date
ECIEPI201731525A ECSP17031525A (es) 2014-05-09 2017-05-23 Composiciones novedosas, usos y métodos para hacerlas
ECSENADI201849420A ECSP18049420A (es) 2014-05-09 2018-06-29 Composiciones novedosas, usos y métodos para hacerlas

Country Status (33)

Country Link
US (1) US9512123B2 (es)
EP (2) EP3219716B1 (es)
JP (2) JP6188179B2 (es)
KR (3) KR101890505B1 (es)
CN (2) CN106995443B (es)
AU (3) AU2015255738C1 (es)
BR (1) BR112016026150B1 (es)
CA (2) CA2974960A1 (es)
CL (2) CL2016002798A1 (es)
CY (1) CY1120935T1 (es)
DK (1) DK3140305T3 (es)
EA (1) EA034235B1 (es)
EC (3) ECSP16088687A (es)
ES (1) ES2679628T3 (es)
HR (1) HRP20181105T1 (es)
HU (1) HUE039733T2 (es)
IL (2) IL248638B (es)
LT (1) LT3140305T (es)
MX (1) MX388752B (es)
NI (1) NI201600168A (es)
NZ (1) NZ725917A (es)
PE (2) PE20170678A1 (es)
PH (2) PH12016502213B1 (es)
PL (1) PL3140305T3 (es)
PT (1) PT3140305T (es)
RS (1) RS57493B1 (es)
SG (2) SG10201703658SA (es)
SI (1) SI3140305T1 (es)
SM (1) SMT201800418T1 (es)
TR (1) TR201809990T4 (es)
UA (1) UA117182C2 (es)
WO (1) WO2015172123A1 (es)
ZA (1) ZA201607573B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9758518B2 (en) * 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
EP3601286A4 (en) * 2017-03-28 2020-09-23 Pimera, Inc. NEW CRYSTALLINE FORMS OF A POL1 INHIBITOR
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN112300173B (zh) * 2019-07-30 2021-10-01 上海凌达生物医药有限公司 一类含氮多环类化合物、制备方法和用途
MX2022001940A (es) 2019-08-14 2022-05-10 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
CN110606850A (zh) * 2019-09-11 2019-12-24 中山大学 一种3-苯并[4,5]咪唑[1,2-a]吡嗪-1-胺类化合物及其制备方法和应用
CN119930610A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
US20240254117A1 (en) * 2020-12-27 2024-08-01 Shanghai Ringene Biopharma Co., Ltd. Pyrimido-heterocyclic compounds, and preparation method therefor and use thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CN113416197B (zh) * 2021-08-25 2021-12-28 北京鑫开元医药科技有限公司 甲酰胺类衍生物、制备方法、药物组合物及应用
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN114276354B (zh) * 2022-01-07 2023-06-02 中山大学 1-氨基苯并[4,5]咪唑并[1,2-a]吡嗪-3-甲酰胺类化合物及其制备和应用
CN114539265B (zh) * 2022-03-02 2023-07-21 中山大学 靶向a2a的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7709746A (nl) * 1976-09-09 1978-03-13 Hoechst Ag Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen.
DE2929414A1 (de) * 1979-07-20 1981-02-05 Hoechst Ag Pyrimido- eckige klammer auf 5',4' zu 5,6 eckige klammer zu -pyrido- eckige klammer auf 1,2-a eckige klammer zu -benzimidazole, verfahren zu ihrer herstellung und deren verwendung
DE3502689A1 (de) * 1985-01-26 1986-07-31 Hoechst Ag, 6230 Frankfurt Elektrophotographisches aufzeichnungsmaterial
EP0647226B1 (de) * 1992-06-22 1997-09-03 Boehringer Ingelheim Kg 9-AMINO-PYRIDAZINO 4',5' : 3,4]PYRROLO- 2,1-a]ISOCHINOLINE UND DEREN VERWENDUNG FÜR DIE HERSTELLUNG VON PHARMAZEUTISCHEN ZUBEREITUNGEN
DE19509043A1 (de) * 1995-03-03 1996-09-05 Bayer Ag Cyanierung von Doppelbindungssystemen
US6960585B2 (en) * 2000-10-03 2005-11-01 Bristol-Myers Squibb Company Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
US7507727B2 (en) 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
US7354916B2 (en) 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
NZ543006A (en) 2003-04-07 2009-03-31 Cylene Pharmaceuticals Inc Substituted quinobenzoxazine analogs
AU2005286965B2 (en) 2004-09-17 2009-10-22 Senhwa Biosciences, Inc. Quinolone analogs as cell proliferation inhibitors
US7652134B2 (en) 2004-09-17 2010-01-26 Cylene Pharmaceuticals, Inc. Methods for converting quinolone esters into quinolone amides
ITMI20042476A1 (it) * 2004-12-23 2005-03-23 Cell Therapeutics Europe Srl Derivati indolici ad attivita' antitumorale
US7402579B2 (en) 2005-04-15 2008-07-22 Cylene Pharmaceuticals, Inc. Quinobenzoxazine analogs and compositions
EP1928887B1 (en) 2005-08-05 2014-12-17 Senhwa Biosciences, Inc. Methods of preparing quinolone analogs
JP5119154B2 (ja) * 2005-09-22 2013-01-16 インサイト・コーポレイション Ｊａｎｕｓキナーゼの四環系阻害剤
US8142909B2 (en) 2006-02-10 2012-03-27 Universal Display Corporation Blue phosphorescent imidazophenanthridine materials
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
US20100063046A1 (en) * 2006-05-17 2010-03-11 Whitten Jeffrey P Tetracyclic imidazole analogs
DE102006051796A1 (de) 2006-11-03 2008-05-08 Merck Patent Gmbh Triaza-benzo[e]azulenderivate
DK3092901T3 (da) 2007-10-05 2020-05-18 Senhwa Biosciences Inc Quinolonanaloger og fremgangsmåder relateret dertil
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
CN102119158B (zh) 2008-11-03 2015-09-09 株式会社Lg化学 含氮杂环化合物及使用该化合物的有机电子器件
US8124770B2 (en) 2009-04-01 2012-02-28 Beatriz Zayas Fluorescent cellular markers
CN101781312B (zh) * 2009-12-30 2012-09-26 中国科学院广州生物医药与健康研究院 一种吲哚衍生物的合成方法
US8637529B2 (en) 2010-06-11 2014-01-28 AbbYie Inc. Pyrazolo[3,4-d]pyrimidine compounds
CN103533934B (zh) * 2011-03-17 2016-03-30 特尔汗什莫尔医学基础设施研究和服务公司 用于治疗自身免疫性疾病的喹诺酮类似物
KR101561730B1 (ko) * 2012-02-06 2015-10-22 주식회사 엘지화학 질소원소를 함유한 헤테로고리 유도체 및 이를 이용한 유기 전자 소자

Also Published As

Publication number Publication date
PH12016502213B1 (en) 2018-09-12
SG10201703658SA (en) 2017-06-29
US9512123B2 (en) 2016-12-06
ECSP18049420A (es) 2018-07-31
JP2017514889A (ja) 2017-06-08
JP2017101038A (ja) 2017-06-08
UA117182C2 (uk) 2018-06-25
EP3140305A1 (en) 2017-03-15
IL264454A (en) 2019-02-28
CL2016002798A1 (es) 2017-03-10
CA2948173C (en) 2018-06-19
KR102044648B1 (ko) 2019-11-13
CN106995443A (zh) 2017-08-01
PL3140305T3 (pl) 2018-10-31
WO2015172123A1 (en) 2015-11-12
ECSP17031525A (es) 2017-06-30
CY1120935T1 (el) 2019-12-11
AU2015255738A1 (en) 2016-11-24
AU2017203955A1 (en) 2017-07-06
CN106459068B (zh) 2019-01-22
RS57493B1 (sr) 2018-10-31
KR101890505B1 (ko) 2018-09-28
CL2017000372A1 (es) 2017-09-08
MX2016014555A (es) 2017-05-30
PE20170131A1 (es) 2017-03-19
PE20170678A1 (es) 2017-06-03
LT3140305T (lt) 2018-09-10
IL248638B (en) 2019-02-28
US20160326176A1 (en) 2016-11-10
EP3219716B1 (en) 2024-12-25
CN106995443B (zh) 2022-01-11
PT3140305T (pt) 2018-07-24
HUE039733T2 (hu) 2019-01-28
EA034235B1 (ru) 2020-01-20
PH12016502213A1 (en) 2017-01-16
CN106459068A (zh) 2017-02-22
MX388752B (es) 2025-03-20
SG11201609171XA (en) 2016-12-29
CA2948173A1 (en) 2015-11-12
EP3219716A1 (en) 2017-09-20
BR112016026150B1 (pt) 2019-11-05
NI201600168A (es) 2017-01-26
AU2015255738B2 (en) 2017-04-27
TR201809990T4 (en) 2018-08-27
CA2974960A1 (en) 2015-11-12
SI3140305T1 (sl) 2018-09-28
EP3140305A4 (en) 2017-03-15
KR20180118806A (ko) 2018-10-31
HRP20181105T1 (hr) 2018-09-21
ZA201607573B (en) 2018-08-30
EA201692269A1 (ru) 2017-04-28
AU2015255738C1 (en) 2017-09-28
NZ725917A (en) 2017-07-28
PH12017500660A1 (en) 2019-03-04
EP3140305B1 (en) 2018-04-18
AU2017202145B2 (en) 2019-02-21
KR20160144509A (ko) 2016-12-16
DK3140305T3 (en) 2018-07-30
AU2017202145A1 (en) 2017-04-20
JP6188179B2 (ja) 2017-08-30
KR20170042821A (ko) 2017-04-19
SMT201800418T1 (it) 2018-09-13
ES2679628T3 (es) 2018-08-29

Similar Documents

Publication Publication Date Title
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
PH12018500718A1 (en) Compounds useful as modulators of trpm8
ECSP17023281A (es) Inhibidores de mk2 y sus usos
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
MX375352B (es) Reguladores de nrf2.
GEP20217239B (en) Pharmaceutical composition
MX2017014956A (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
CL2017001046A1 (es) Inhibidoes del bromodominio
MX2019013645A (es) Inhibidores de quinasa y usos de los mismos.
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
MX2018000511A (es) Derivados de fenoximetilo.
UY37018A (es) Inhibidores bicíclicos de pad4
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
GEP20217240B (en) Pharmaceutical composition
MX2017011116A (es) Composiciones novedosas, usos y metodos para hacerlas.
DOP2016000211A (es) Pirazinas moduladoras de gpr6
MX2018001315A (es) Inhibidores de fucosidasa.
MX371158B (es) Compuestos inhibidores de pde2.